US92532F1003
US92532F1003
Vertex Pharmaceuticals Incorpor
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 12.001.300.000 | 11.020.100.000 | 8.9% |
| Cost of Revenue | 1.651.300.000 | 1.530.500.000 | 7.9% |
| Gross Profit | 10.350.000.000 | 9.489.600.000 | 9.1% |
| 5.795.600.000 | 9.723.000.000 | 40.4% | |
| Operating Income | 4.554.400.000 | -233.400.000 | 2051.3% |
| Pretax Income | 4.643.200.000 | 248.500.000 | 1768.5% |
| Net Income Common Stockholders | 3.953.200.000 | -535.600.000 | 838.1% |
| -- | -- | -- | |
| -- | -- | -- |